Healthcare stocks with plenty of potential -- and low share prices
A terrifying new cancer study out of Johns Hopkins Medicine confirms a suspicion some researchers have harbored all along.
Sequenom decodes its way to big gains in December after settling a long-standing dispute with a larger rival. See what this could mean for investors over the long run.
A full human genome can now be sequenced for $1,000. That's still a little pricey for mass adoption, but Illumina and Pacific Biosciences could bring the cost down even further -- opening up the genomics floodgates.
These 10 stocks were the top large-cap performers in healthcare during 2014.
Sequenom splices and dices its ways to huge gains after announcing the settlement of a long-standing patent dispute with a rival.
What investors need to know about Pacific Biosciences' third quarter performance.
Thermo Fisher Scientific's future rests on three pillars of growth, and a big-name acquisition may tip the scales in their favor.
Illumina (ILMN) seems unbeatable in sequencing today, but tomorrow could bring changes no one can anticipate.
It's the leader in a fast-growing young industry, but does Illumina (ILMN) have what it takes to trounce the market over the long term?